Correction

Correction: A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care

Christopher J Longo1, Daren K Heyland2, Harold N Fisher3, Robert A Fowler4, Claudio M Martin5 and Andrew G Day6

1McMaster University, Main Street West, Hamilton, Ontario, Canada, L8S 4M4
2Kingston General Hospital, Queen's University, Stuart Street, Kingston, Ontario, Canada, K7L 2V7
3Eli Lilly Canada Inc., Danforth Avenue, Scarborough, Ontario, Canada, M1N 2E8
4Sunnybrook Health Sciences Centre, Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5
5London Health Sciences Centre, Commissioneres Road East, London, Ontario, Canada, N6A 5W9
6Clinical Research Centre, Kingston General Hospital, Stuart Street, Kingston, Ontario, Canada, K7L 2V7

Corresponding author: Christopher J Longo, cjlongo@mcmaster.ca

Published: 20 October 2008

Critical Care 2008, 12:429 (doi:10.1186/cc7031)

Available online http://ccforum.com/content/12/5/429

© 2008 BioMed Central Ltd

Following the publication of the above article [1], we discovered the omission of the legend from Figures 2 through Figure 5. The following legends should be included for each of these figures:

**Figure 2 legend**
Model based estimation for mean PCS and standard error bar for all patients. Average group differences: \( P = 0.04 \). APC, activated protein C; PCS, physical component score.

**Figure 3 legend**
Model based estimation for mean RP and standard error bar for all patients. Average group differences: \( P = 0.10 \). APC, activated protein C; RP, role physical.

**Figure 4 legend**
Model based estimation for mean BP and standard error bar for all patients. Average group differences: \( P = 0.14 \). APC, activated protein C; BP, bodily pain.

**Figure 5 legend**
Model based estimation for mean PF and standard error bar for all patients. Average group differences: \( P = 0.12 \). APC, activated protein C; PF, physical function.

**Reference**
1. Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin C, Day A: A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care. Crit Care 2007, 11:R128.